|
Mutation Information
|
Mutation Site
|
L180M |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Combined Mutation
|
rt.L180M+rt.M204V+rt.T184A;rt.L180M+rt.M204V;rt.L80I+rt.M204I+rt.L180M;rt.M204V+rt.L180M+rt.V173L;rt.M204I+rt.L180M;rt.L80V+rt.M204V+rt.L180M;rt.M204V+rt.L180M |
|
Viral Reference
|
FJ023659;
AB064312;
AF223963;
X75664;
JF754597;
FJ386590;
AB014376;
AB112471;
AY217358;
D23679;
AJ309370;
AY233288 |
|
Relevant Drug
|
lamivudine (LAM) |
|
Country
|
China |
Literature Information
|
PubMed PMID
|
30368502
|
|
Disease
|
HBV-HIV coinfection
|
|
Published Year
|
2018 |
|
Journal
|
Intervirology |
|
Title
|
High Prevalence of HBV Lamivudine-Resistant Mutations in HBV/HIV Co-Infected Patients on Antiretroviral Therapy in the Area with the Highest Prevalence of HIV/HBV Co-Infection in China. |
|
Author
|
Jia HH,Li KW,Chen QY,Wang XY,Harrison TJ,Liang SJ,Yang QL,Wang C,Hu LP,Ren CC,Fang ZL |
|
Evidence
|
The major pattern of lamivudine (3TC)-resistant mutations is L180M+M204I+L80I (35.7%).
|
|
|
HBV Mutation Detail Information